Religious Orders Study and Rush Memory and Aging Project

Background: The Religious Orders Study and Rush Memory and Aging Project are both ongoing longitudinal clinical-pathologic cohort studies of aging and Alzheimer’s disease (AD). Objectives: To summarize progress over the past five years and its implications for understanding neurodegenerative disease...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Alzheimer's disease 2018-01, Vol.64 (s1), p.S161-S189
Main Authors: Bennett, David A., Buchman, Aron S., Boyle, Patricia A., Barnes, Lisa L., Wilson, Robert S., Schneider, Julie A.
Format: Article
Language:English
Subjects:
Adults
Aging
Aging - genetics
Aging - pathology
Aging - psychology
Alzheimer Disease - drug therapy
Alzheimer Disease - epidemiology
Alzheimer Disease - genetics
Alzheimer Disease - pathology
Alzheimer's disease
Blood & organ donations
Clinical decision making
Cognitive ability
Decision making
Dementia
Dementia disorders
Drug discovery
Humans
Memory
Nervous system
Neurodegenerative diseases
Neurological diseases
Neurosciences
Older people
Religious Personnel
Risk analysis
Risk factors
Studies
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The Religious Orders Study and Rush Memory and Aging Project are both ongoing longitudinal clinical-pathologic cohort studies of aging and Alzheimer’s disease (AD). Objectives: To summarize progress over the past five years and its implications for understanding neurodegenerative diseases. Methods: Participants in both studies are older adults who enroll without dementia and agree to detailed longitudinal clinical evaluations and organ donation. The last review summarized findings through the end of 2011. Here we summarize progress and study findings over the past five years and discuss new directions for how these studies can inform on aging and AD in the future. Results: We summarize 1) findings on the relation of neurobiology to clinical AD; 2) neurobiologic pathways linking risk factors to clinical AD; 3) non-cognitive AD phenotypes including motor function and decision making; 4) the development of a novel drug discovery platform. Conclusion: Complexity at multiple levels needs to be understood and overcome to develop effective treatments and preventions for cognitive decline and AD dementia.
ISSN:1387-2877
1875-8908
1875-8908
DOI:10.3233/JAD-179939